| Application number | Title of the application | Filing Date | Status |
|---|
| 08/832988 | INHIBITORS OF PROTEIN TYROSINE-PHOSPHATASE ALPHA FOR TREATMENT OF TUMORS | Apr 2, 1997 | Abandoned |
| 08/708661 | GENE THERAPY FOR CONGESTIVE HEART FAILURE | Sep 4, 1996 | Pending |
| 08/592525 | ENDOSCOPIC GENE THERAPY | Jan 25, 1996 | Abandoned |
Array
(
[id] => 3812750
[patent_doc_number] => 05789244
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1998-08-04
[patent_title] => 'Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems'
[patent_app_type] => 1
[patent_app_number] => 8/584077
[patent_app_country] => US
[patent_app_date] => 1996-01-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 5091
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/789/05789244.pdf
[firstpage_image] =>[orig_patent_app_number] => 584077
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/584077 | Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems | Jan 7, 1996 | Issued |
Array
(
[id] => 3714565
[patent_doc_number] => 05616491
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1997-04-01
[patent_title] => 'Knockout mice'
[patent_app_type] => 1
[patent_app_number] => 8/528363
[patent_app_country] => US
[patent_app_date] => 1995-09-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 13
[patent_no_of_words] => 9914
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/616/05616491.pdf
[firstpage_image] =>[orig_patent_app_number] => 528363
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/528363 | Knockout mice | Sep 13, 1995 | Issued |
Array
(
[id] => 3621911
[patent_doc_number] => 05602025
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1997-02-11
[patent_title] => 'Non-tumorigenic cell lines for expression of genes'
[patent_app_type] => 1
[patent_app_number] => 8/468195
[patent_app_country] => US
[patent_app_date] => 1995-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 4
[patent_no_of_words] => 4875
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 8
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/602/05602025.pdf
[firstpage_image] =>[orig_patent_app_number] => 468195
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/468195 | Non-tumorigenic cell lines for expression of genes | Jun 5, 1995 | Issued |
Array
(
[id] => 3567668
[patent_doc_number] => 05538713
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1996-07-23
[patent_title] => 'Primordial implants in immunodeficient hosts'
[patent_app_type] => 1
[patent_app_number] => 8/462766
[patent_app_country] => US
[patent_app_date] => 1995-06-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3373
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/538/05538713.pdf
[firstpage_image] =>[orig_patent_app_number] => 462766
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/462766 | Primordial implants in immunodeficient hosts | Jun 4, 1995 | Issued |
Array
(
[id] => 3774624
[patent_doc_number] => 05849996
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1998-12-15
[patent_title] => 'BCR/ABL transgenic animals as models for Philadelphia chromosome positive chronic myelogenous and acute lymphoblastic leukemia'
[patent_app_type] => 1
[patent_app_number] => 8/463467
[patent_app_country] => US
[patent_app_date] => 1995-06-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 17
[patent_no_of_words] => 9078
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/849/05849996.pdf
[firstpage_image] =>[orig_patent_app_number] => 463467
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/463467 | BCR/ABL transgenic animals as models for Philadelphia chromosome positive chronic myelogenous and acute lymphoblastic leukemia | Jun 4, 1995 | Issued |
| 08/459587 | IDENTIFICATION OF A HUMAN CYTOMEGALOVIRUS GENE REGION INVOLVED IN DOWN-REGULATION OF MHC CLASS I HEAVY CHAIN EXPRESSION | Jun 1, 1995 | Abandoned |
Array
(
[id] => 3509121
[patent_doc_number] => 05569812
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1996-10-29
[patent_title] => 'Nude mouse model for human neoplastic disease'
[patent_app_type] => 1
[patent_app_number] => 8/459730
[patent_app_country] => US
[patent_app_date] => 1995-06-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5507
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/569/05569812.pdf
[firstpage_image] =>[orig_patent_app_number] => 459730
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/459730 | Nude mouse model for human neoplastic disease | Jun 1, 1995 | Issued |
Array
(
[id] => 3722894
[patent_doc_number] => 05670134
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1997-09-23
[patent_title] => 'Method for evaluating and modifying biological activity'
[patent_app_type] => 1
[patent_app_number] => 8/456330
[patent_app_country] => US
[patent_app_date] => 1995-06-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 7525
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 118
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/670/05670134.pdf
[firstpage_image] =>[orig_patent_app_number] => 456330
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/456330 | Method for evaluating and modifying biological activity | May 31, 1995 | Issued |
Array
(
[id] => 3657988
[patent_doc_number] => 05591669
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1997-01-07
[patent_title] => 'Transgenic mice depleted in a mature lymphocytic cell-type'
[patent_app_type] => 1
[patent_app_number] => 8/454034
[patent_app_country] => US
[patent_app_date] => 1995-05-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 24
[patent_no_of_words] => 15212
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 151
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/591/05591669.pdf
[firstpage_image] =>[orig_patent_app_number] => 454034
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/454034 | Transgenic mice depleted in a mature lymphocytic cell-type | May 29, 1995 | Issued |
Array
(
[id] => 3536538
[patent_doc_number] => 05557032
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1996-09-17
[patent_title] => 'Knockout mice'
[patent_app_type] => 1
[patent_app_number] => 8/451691
[patent_app_country] => US
[patent_app_date] => 1995-05-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 9910
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/557/05557032.pdf
[firstpage_image] =>[orig_patent_app_number] => 451691
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/451691 | Knockout mice | May 25, 1995 | Issued |
Array
(
[id] => 3665295
[patent_doc_number] => 05625127
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1997-04-29
[patent_title] => 'Extended human hematopoiesis in a heterologous host'
[patent_app_type] => 1
[patent_app_number] => 8/434706
[patent_app_country] => US
[patent_app_date] => 1995-05-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2349
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/625/05625127.pdf
[firstpage_image] =>[orig_patent_app_number] => 434706
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/434706 | Extended human hematopoiesis in a heterologous host | May 3, 1995 | Issued |
Array
(
[id] => 3644188
[patent_doc_number] => 05639440
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1997-06-17
[patent_title] => 'Method for evaluating immunogenicity'
[patent_app_type] => 1
[patent_app_number] => 8/428932
[patent_app_country] => US
[patent_app_date] => 1995-04-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 7582
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 156
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/639/05639440.pdf
[firstpage_image] =>[orig_patent_app_number] => 428932
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/428932 | Method for evaluating immunogenicity | Apr 24, 1995 | Issued |
Array
(
[id] => 3603945
[patent_doc_number] => 05589155
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1996-12-31
[patent_title] => 'Mutagenesis testing using transgenic non-human animals carrying test DNA sequences'
[patent_app_type] => 1
[patent_app_number] => 8/398933
[patent_app_country] => US
[patent_app_date] => 1995-03-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 8
[patent_no_of_words] => 7878
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 166
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/589/05589155.pdf
[firstpage_image] =>[orig_patent_app_number] => 398933
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/398933 | Mutagenesis testing using transgenic non-human animals carrying test DNA sequences | Mar 5, 1995 | Issued |
| 08/379105 | LIVE ANIMAL MUTAGENESIS SYSTEMS FOR TESTING MUTAGENTIC AGENTS IN VIVO | Jan 26, 1995 | Abandoned |
Array
(
[id] => 4005258
[patent_doc_number] => 05888774
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1999-03-30
[patent_title] => 'Recombinant DNA molecules and expression vectors for erythropoietin'
[patent_app_type] => 1
[patent_app_number] => 8/358918
[patent_app_country] => US
[patent_app_date] => 1994-12-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 15273
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/888/05888774.pdf
[firstpage_image] =>[orig_patent_app_number] => 358918
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/358918 | Recombinant DNA molecules and expression vectors for erythropoietin | Dec 18, 1994 | Issued |
Array
(
[id] => 3620946
[patent_doc_number] => 05688773
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1997-11-18
[patent_title] => 'Method of selectively destroying neoplastic cells'
[patent_app_type] => 1
[patent_app_number] => 8/330523
[patent_app_country] => US
[patent_app_date] => 1994-10-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 33
[patent_figures_cnt] => 46
[patent_no_of_words] => 35903
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 85
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/688/05688773.pdf
[firstpage_image] =>[orig_patent_app_number] => 330523
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/330523 | Method of selectively destroying neoplastic cells | Oct 27, 1994 | Issued |
Array
(
[id] => 3495548
[patent_doc_number] => 05532158
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1996-07-02
[patent_title] => 'Interleukin-2 receptor deficient mammals'
[patent_app_type] => 1
[patent_app_number] => 8/326896
[patent_app_country] => US
[patent_app_date] => 1994-10-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 8
[patent_no_of_words] => 9371
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/532/05532158.pdf
[firstpage_image] =>[orig_patent_app_number] => 326896
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/326896 | Interleukin-2 receptor deficient mammals | Oct 20, 1994 | Issued |